ArticleAtherosclerosis plus2026
Plasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk.
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Building on our previous isolation of plaque-derived small extracellular vesicles (sEVs) from carotid atherosclerotic stenosis (CAS) patients, this study aimed to identify plasma sEV-encapsulated miRNAs that reflect plaque vulnerability and predict clinical outcomes, based on differentially expressed miRNAs identified in sEVs from stable versus vulnerable plaques. Methods: CAS patients were retrospectively enrolled into four complementary cohorts: (1) a sequencing cohort (n = 12) for miRNA profiling of plaque-derived sEVs; (2) a discovery cohort (n = 62) to identify candidate plasma-derived sEV miRNAs associated with plaque vulnerability; and (3) validation cohort 1 (n = 180; endarterectomy cases) and (4) validation cohort 2 (n = 326; stenting cases) for validating the diagnostic efficacy of the identified plasma-derived sEV miRNAs. Candidate miRNAs were quantified using a High-throughput nano-bio chip integrated system (HNCIB). Their associations with plaque vulnerability and 3-year post-endarterectomy major adverse cardiovascular events (MACE) were analyzed. Results: MiRNA sequencing revealed significant upregulation of miR-660-5p in vulnerable plaque-derived sEVs. Its expression levels showed a significant positive correlation between matched plaque- and plasma-derived sEVs from the same patient. Moreover, plasma-derived sEV miR-660-5p levels were independently associated with carotid plaque vulnerability in both validation cohorts, defined either by histopathological criteria (endarterectomy cases) or the clinically validated Plaque-Reporting and Data System (RADS) criteria (stenting cases). Additionally, elevated plasma-derived sEV miR-660-5p levels were also associated with a higher risk of 3-year post-endarterectomy MACE. Conclusion: Plasma-derived sEV miR-660-5p represents a promising non-invasive biomarker for assessing carotid plaque vulnerability and predicting 3-year MACE risk following carotid endarterectomy, offering potential for improved risk stratification and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.